Celcuity Inc. 2024 Annual Report (10-K) Summary
Business Context and Reporting Period
Company: Celcuity Inc. (CELC)
Reporting Period: Fiscal year ended December 31, 2024
Business Model: Clinical-stage biotechnology company focused on developing targeted therapies for solid tumors. The company has no revenue to date and relies on equity and debt financing.
Lead Asset: Gedatolisib, an intravenous inhibitor targeting all Class I PI3K isoforms and mTORC1/mTORC2 complexes. It holds Fast Track and Breakthrough Therapy designations for HR+/HER2- advanced breast cancer.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(111.8) million | $(63.8) million |
| Operating Expenses | $113.3 million | $66.2 million |
| Research & Development | $104.2 million | $60.6 million |
| General & Administrative | $9.1 million | $5.6 million |
| Interest Expense | $(10.3) million | $(5.3) million |
| Interest Income | $11.8 million | $7.8 million |
| Cash & Short-Term Investments | $235.1 million | $180.6 million |
| Total Debt (Principal) | $100.0 million | $35.0 million |
| Accumulated Deficit | $(271.9) million | $(160.1) million |
Material Changes vs. Prior Period
- Increased Burn Rate: Net loss increased 75% to $111.8 million, driven primarily by a 72% increase in R&D expenses ($43.6 million increase) due to the expansion of Phase 3 trials (VIKTORIA-1 and VIKTORIA-2) and the initiation of the CELC-G-201 prostate cancer trial.
- Debt Financing: In May 2024, the company entered an Amended and Restated Loan Agreement, increasing total debt principal from $35.0 million to $100.0 million. This included $61.7 million in new borrowings.
- Equity Financing: The company raised approximately $60.0 million in gross proceeds from a follow-on equity offering in May 2024 and utilized its At-The-Market (ATM) facility for additional proceeds.
- Interest Income: Interest income rose 51% to $11.8 million, offsetting a portion of the operating loss, due to higher cash balances from recent financing activities.
Guidance, Outlook, and Risks
Clinical Outlook:
- VIKTORIA-1 (Breast Cancer): Enrollment for the PIK3CA wild-type cohort is complete. Topline data is expected in Q2 2025. The PIK3CA mutant cohort continues to enroll, with data expected in Q4 2025.
- VIKTORIA-2 (Breast Cancer): A Phase 3 first-line trial. Site activation is underway; first patient dosing is expected in Q2 2025.
- CELC-G-201 (Prostate Cancer): Phase 1b/2 trial ongoing. Preliminary Phase 1b data expected by end of Q2 2025.
Liquidity: Management believes current cash, investments, and available debt borrowings are sufficient to fund operations through 2026.
Key Risks:
- Capital Requirements: The company has no revenue and requires significant additional capital to complete clinical trials and commercialize gedatolisib. Future financing may result in dilution.
- Clinical Uncertainty: Failure to demonstrate efficacy or safety in Phase 3 trials would materially harm the business.
- Intellectual Property: Reliance on a license agreement with Pfizer for gedatolisib; termination could result in loss of rights.
- Debt Covenants: The loan agreement includes financial covenants and milestone-based tranches that must be met to access additional funding.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $235.1 million cash position against the projected burn rate for the VIKTORIA-2 trial and potential commercialization costs.
- Debt Terms: Review the specific financial covenants and milestone triggers in the Innovatus/Oxford loan agreement that govern access to the remaining $80 million in committed tranches.
- Clinical Timelines: Monitor the Q2 2025 data readout for the VIKTORIA-1 wild-type cohort as a critical value inflection point.
- Dilution Risk: Assess the impact of outstanding warrants (approx. 11.3 million shares) and options (approx. 4.3 million shares) on future share count.
- Pfizer License: Confirm compliance with diligence obligations under the Pfizer license agreement to avoid termination risks.